Enliven Therapeutics, Inc. (ELVN) vs Tarsus Pharmaceuticals, Inc. (TARS)
A side-by-side comparison of Enliven Therapeutics, Inc. and Tarsus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ELVN
Enliven Therapeutics, Inc.
$42.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TARS
Tarsus Pharmaceuticals, Inc.
$74.11HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — ELVN vs TARS
growth of $100 · dividends reinvested · last 6yELVN -41.6% (-8.6%/yr)TARS +261.8% (+23.9%/yr)TARS compounded faster over this window
Log scale — wide-divergence pair
ELVN TARS
ELVN vs TARS: by the numbers
- •TARS is the larger company ($3.19B vs $3.03B market cap).
- •Both run net losses; ELVN's is the smaller (0.00% vs -7.67% net margin).
Metrics side by side
Valuation
| Metric | ELVN | TARS |
|---|---|---|
| P/S ratio | N/A | 5.26 |
| P/B ratio | 3.38 | 9.20 |
| FCF yield | N/A | 1.93% |
Profitability
| Metric | ELVN | TARS |
|---|---|---|
| Gross margin | 0.00% | 90.59% |
| Operating margin | 0.00% | -8.00% |
| Net margin | 0.00% | -7.67% |
| ROE | -11.83% | -13.40% |
| ROIC | -13.88% | -11.15% |
Growth (annualized)
| Metric | ELVN | TARS |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 61.36% |
| Total return CAGR (5Y) | 24.57% | 28.33% |
Frequently asked
- How have ELVN and TARS total returns compared?
- Over the past 5 years, ELVN delivered 24.57% and TARS delivered 28.33% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Enliven Therapeutics ROETarsus Pharmaceuticals ROEEnliven Therapeutics operating marginTarsus Pharmaceuticals operating marginEnliven Therapeutics revenue growthTarsus Pharmaceuticals revenue growthEnliven Therapeutics free cash flowTarsus Pharmaceuticals free cash flow
Enliven Therapeutics & Tarsus Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.